Table 2.
Overview of the number of women with filled prescriptions as registered in the Norwegian Prescription Database (NorPD) and self-reported medication use in the baseline (Q1) and follow-up questionnaires (Q2)
| Intervention group | Control group | Intervention group | Control group | Impact of a pharmacist consultation on medication use in the 2nd trimester | ||
|---|---|---|---|---|---|---|
| Medication use in the 1st trimester | Medication use in the 1st trimester | Medication use in the 2nd trimester | Medication use in the 2nd trimester | |||
| n (%) | n (%) | n (%) | n (%) | Crude OR (95% CI) | Adjusted OR* (95% CI) | |
| Filled prescriptions as registered in the NorPD**** | ||||||
| A: Alimentary tract and metabolism | 29 (28.2) | 37 (29.4) | 24 (23.3) | 34 (26.9) | 0.8 (0.4, 1.5) | 0.7 (0.3, 1.7) |
| B: Blood and blood forming organs | 15 (14.6) | 21 (16.7) | 16 (15.5) | 26 (20.6) | 0.7 (0.4, 1.4) | 0.6 (0.2, 1.9) |
| G: Genito-urinary system and sex hormones | 37 (35.9) | 51 (40.5) | 23 (22.3) | 48 (38.1) | 0.5 (0.2, 0.8) | 0.4 (0.2, 0.8) |
| H: Systemic hormonal preparations | 16 (15.5) | 28 (22.2) | 13 (12.6) | 26 (20.6) | 0.6 (0.3, 1.1) | 0.6 (0.2, 1.9) |
| J: Anti-infectives for systemic use | 41 (39.8) | 41 (32.5) | 36 (34.9) | 47 (37.3) | 0.9 (0.5, 1.6) | 0.7 (0.3, 1.3) |
| N: Nervous system | 18 (17.5) | 35 (27.8) | 14 (13.6) | 31 (24.6) | 0.5 (0.2, 0.9) | 0.6 (0.2, 1.6) |
| R: Respiratory system | 36 (34.9) | 39 (30.9) | 32 (31.1) | 39 (30.9) | 1.0 (0.6, 1.8) | 0.8 (0.4, 1.7) |
| Total*** | 57 (55.3) | 62 (49.2) | 46 (44.7) | 65 (51.6) | 0.8 (0.4, 1.3) | 0.7 (0.4, 1.2) |
| Self-reported medication use** | ||||||
| A: Alimentary tract and metabolism | 7 (6.8) | 10 (7.9) | 21 (20.4) | 32 (25.4) | 0.8 (0.4, 1.4) | 0.8 (0.4, 1.5) |
| N: Nervous system | 6 (5.8) | 10 (7.9) | 46 (44.6) | 59 (46.8) | 0.9 (0.5, 1.5) | 1.0 (0.6, 1.7) |
| R: Respiratory system | 25 (24.3) | 34 (26.9) | 28 (27.2) | 40 (31.7) | 0.8 (0.5, 1.4) | 0.8 (0.4, 1.5) |
| Total**** | 36 (34.9) | 45 (35.7) | 59 (57.3) | 83 (65.9) | 0.7 (0.4, 1.2) | 0.7 (0.4, 1.2) |
The impact of a pharmacist consultation on medication use in the second trimester in the intervention (N = 103) and control groups (N = 126) are presented as crude ORs and adjusted ORs
NorPD Norwegian Prescription Database, n Number of women
*Adjusted for medication use and employment status at baseline
**ATC codes S (sensory system) and M (musculoskeletal system) are not included in this table because the number of women who reported them was below 10
***Total number of women who reported at least one medication/ had at least one filled prescription registered in the NorPD
****ATC codes C (cardiovascular system), D (dermatologicals), L (antineoplastic and immunomodulating agents), M (musculoskeletal system), P (antiparasitic products, insecticides and repellents), S (sensory system), and V (various) were not included in this table as the number of women who reported them was below 10